0 Replies
Stories include:
@FierceBiotech: Study: Less than 1% of cancer patients enrolled in a clinical trial. Piece Very troubling.
@JohnCFierce: 52% of hospital/pharmacy purchasing agents bought drugs from gray market vendors in past 2 years. Price gouging? Article Contine Reading & Discuss→
0 Replies
HAMDEN, Conn., and BOULDER, Colo., August 25, 2011 – RxGen, a specialty preclinical contract research organization, and miRagen Therapeutics, Inc., a preclinical-stage biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the award of a Small Business Innovation Research... Contine Reading & Discuss→
0 Replies
Stories include:
Today's the day for some eligible Merck ($MRK) employees to give the yea or nay on early retirement. As the Philadelphia Inquirer reports, union officials say early retirement papers are due--and what happens next depends upon how many Merck people choose for an early exit. The deadline comes... Contine Reading & Discuss→
0 Replies
London, February 7, 2011 – Further to the announcement dated 7 September 2010, made in response to share price movement, Silence Therapeutics plc (AIM: SLN) (“Silence” or the “Company”) confirms it is no longer in discussions which may lead to an offer for the Company. The Board is not aware... Contine Reading & Discuss→
0 Replies
PASADENA, Calif. - August 8, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 third quarter ended June 30, 2011. Contine Reading & Discuss→
